| Ms Patricia Diane Wise, PA | |
|
433 W High St, Bryan, OH 43506-1690 | |
| (419) 636-1131 | |
| (419) 636-3100 |
| Full Name | Ms Patricia Diane Wise |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 14 Years |
| Location | 433 W High St, Bryan, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720388481 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 50.007054RX (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Hospitals And Wellness Centers | Bryan, OH | Hospital |
| Community Hospitals And Wellness Centers | Montpelier, OH | Hospital |
| Parkview Regional Medical Center | Fort wayne, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Hospitals And Wellness Centers | 7517878093 | 51 |
News Archive
FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Advances in neonatal care for very preterm infants have greatly increased the chances of survival for these fragile infants. However, preterm infants have an increased risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease, which is a major cause of death and lifelong complications.
State lawmakers grapple with health care issues including establishing a new monitor for disabled care in New York, avoiding cuts for undocumented immigrant care in D.C. and a Massachusetts revamp of the state medical board.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Patricia Diane Wise, PA 433 W High St, Bryan, OH 43506-1690 Ph: (419) 636-1131 | Ms Patricia Diane Wise, PA 433 W High St, Bryan, OH 43506-1690 Ph: (419) 636-1131 |
News Archive
FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Advances in neonatal care for very preterm infants have greatly increased the chances of survival for these fragile infants. However, preterm infants have an increased risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease, which is a major cause of death and lifelong complications.
State lawmakers grapple with health care issues including establishing a new monitor for disabled care in New York, avoiding cuts for undocumented immigrant care in D.C. and a Massachusetts revamp of the state medical board.
› Verified 9 days ago
Mr. Michael W Koenig, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 442 W High St Ste 3, Bryan, OH 43506 Phone: 419-636-4517 Fax: 419-636-6438 |